干细胞领域知识发现平台

免费注册账号

查看全文和研发动态、知识导航以及收藏您喜欢的数据等操作，您需要注册一个免费帐户并登录。

写笔记

您最近的笔记

Drug Name:HG-1063

Regulatory Designations:
Originator Company: Human Genome Sciences Inc Active Companies:

Last Change Date: 2018-03-20

extract

As no development has been reported for some time, this program is assumed to be discontinued. Human Genome Sciences was investigating HG-1063, a program targeting human stem cell antigen-2 (lymphocyte antigen 6 complex, locus E; LY6E; RIG-E; SCA-2; TSA-1; retinoic acid induced gene E; thymic shared antigen 1), for the potential treatment of cancer and immune diseases. In August 2010, the company was seeking to outlicense rights to the technology [ 1122590 ].

Other Drug Names:

HG-1063; LY6E modulator (cancer/immune disease), Human Genome Sciences; RIG-E modulator (cancer/immune disease), Human Genome Sciences; SCA-2 modulator (cancer/immune disease), Human Genome Sciences; TSA-1 modulator (cancer/immune disease), Human Genome Sciences; human stem cell antigen-2 modulator (cancer/immune disease), Human Genome Sciences; lymphocyte antigen 6 complex, locus E modulator (cancer/immune disease), Human Genome Sciences; retinoic acid induced gene E modulator (cancer/immune disease), Human Genome Sciences; thymic shared antigen 1 modulator (cancer/immune disease), Human Genome Sciences

Technologies

Small molecule therapeutic

Development Status (Current)

Human Genome Sciences Inc: US: No Development Reported: Immune disorder: 22-Feb-2012 Human Genome Sciences Inc: US: No Development Reported: Cancer: 22-Feb-2012

Development Status (History)

Human Genome Sciences Inc: US: Discovery: Cancer: 10-Aug-2010 Human Genome Sciences Inc: US: Discovery: Immune disorder: 10-Aug-2010

Drug Development Phase

[Immune disorder: No Development Reported: US Cancer: No Development Reported: US]

Therapy Area:

Cancer; Immune

Highest Status

No Development Reported

Target-based Actions

Lymphocyte antigen modulator

Other Actions

Anticancer; Immunomodulator

Active Indications

更多操作微信 QQ好友 QQ空间新浪微博人人网复制网址打印